Ilunocitinib

What is ilunocitinib?

Ilunocitinib (brand name Zenrelia®) is a medication used to control pruritus (itching) associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age and up-to-date on vaccinations. It is labeled for use in dogs only.

How do I give my pet ilunocitinib?

• Ilunocitinib comes in tablet form. 
• Tablets are given orally (by mouth).
• This medication may be given with or without food.
• If your animal vomits or acts sick after receiving the drug on an empty stomach, try giving the next dose with food or a small treat. If vomiting continues, contact your veterinarian.  
• Give this medication to your pet for the entire time prescribed by your veterinarian, even if it appears that your pet is feeling better.

This medication should start to take effect within a few days, though effects may not be noticeable right away.

What if I miss giving my pet the medication?

If you miss a dose, give it as soon as you remember, and then wait the recommended time as prescribed by your veterinarian for the next dose. Do not give the pet two doses at once.

Are there any potential side effects from ilunocitinib?

Ilunocitinib may cause the following side effects:

• Lack of appetite and/or energy
• Vomiting and/or diarrhea
• Ear infections (otitis externa), other infections

The following reactions are rare, but if they occur, contact your veterinarian immediately:

• An allergic reaction such as irregular breathing, rash, fever, puffiness and swelling around the face
• Fever, severe lack of energy, weakness, pale gums

Drug sensitivities can develop over time with repeated exposure. Your pet may have no reaction after the first few doses, but may develop a sensitivity later. It is important to watch for signs of an allergic reaction over the entire course of treatment.

Based on the results of a vaccine response study, dogs receiving ilunocitinib are at risk of fatal vaccine-induced disease from modified live virus vaccines and inadequate immune response to any vaccine. Discontinue ilunocitinib for at least 28 days to 3 months prior to vaccination and withhold this medication for at least 28 days after vaccination

Other side effects may occur. If you notice anything unusual, contact your veterinarian immediately. This medication is short-acting, meaning that effects will last less than 24 hours, though effects may last longer in pets with kidney or liver disease.

Are there any risk factors for this medication?

DO NOT USE in dogs who:

• are allergic to any component of the drug
• are pregnant or nursing
• are not up-to-date on vaccinations
• have been vaccinated in the previous 28 days
• have severe infections and/or neoplasia
• are currently taking other immunosuppressive medications (e.g., cyclosporine, prednisone)

USE WITH CAUTION in dogs who

• Have decreased liver and/or kidney function

Are there any drug interactions I should be aware of?

Certain medications should be USED WITH CAUTION when given with ilunocitinib, including: 

• Cyclosporine
• Glucocorticoids
• Immunosuppressive agents (e.g., chemotherapeutic agents)

Be sure to tell your veterinarian about any medications (including vitamins, supplements, or herbal therapies) that your pet is taking before starting any new treatment.

Is any monitoring needed with this medication?

• Your veterinarian may assess baseline blood work before starting this medication and may monitor blood work throughout treatment.
• Your veterinarian will schedule follow-up visits for monitoring. In this case, follow your veterinarian’s directions.
• At home, monitor for any abnormal changes. If any occur, discontinue the medication and contact your veterinarian.

How do I store ilunocitinib?

• Store at room temperature of 15°C-25°C (59°F-77°F), with short excursions permitted between 5°C and 40°C (41°F-104°F).
• Keep medication out of reach of children and pets.

What should I do in case of emergency?

If you suspect an overdose or an adverse reaction to the medication, call your veterinary office immediately. If they are not available, follow their directions in contacting an emergency facility. Adverse effects should be reported to the FDA or Health Canada.